false 0001796129 0001796129 2023-05-25 2023-05-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 25, 2023

 

 

Vincerx Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39244   83-3197402
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

 

260 Sheridan Avenue, Suite 400

Palo Alto, California

   94306
(Address of principal executive offices)   (Zip Code)

(650) 800-6676

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.0001 par value per share   VINC   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

Vincerx Pharma, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders on May 25, 2023 (the “Annual Meeting”). The following actions were taken at the Annual Meeting:

 

  1.

The following director nominees were elected to serve as a director until the Company’s 2026 annual meeting of stockholders or until their successors are duly elected and qualified.

 

     For    Withheld    Broker Non-Votes

Dr. Ahmed M. Hamdy

    12,421,149    110,111    4,382,445

Dr. Brian J. Druker

    11,778,507    752,753    4,382,445

 

  2.

The appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the year ending December 31, 2023 was ratified.

 

For

  

Against

  

Abstain

16,905,560   8,063   82

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 30, 2023

 

VINCERX PHARMA, INC.
By:  

/s/ Raquel E. Izumi

  Raquel E. Izumi
  President and Chief Operations Officer
LifeSci Acquisition (NASDAQ:LSACU)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more LifeSci Acquisition Charts.
LifeSci Acquisition (NASDAQ:LSACU)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more LifeSci Acquisition Charts.